Background

This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them.

Methods

We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed.

Results

Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks.

Conclusion

These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks.

Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740)

中文翻译：

---

Erenumab 可预防偏头痛发作，而不仅仅是偏头痛天数：III 期研究的事后分析

背景

这项事后分析旨在评估 erenumab 对发作性偏头痛患者每月偏头痛天数、每月偏头痛发作和发作持续时间的影响，以调查 erenumab 是否真的预防和/或缩短偏头痛发作的发生。

方法

我们对 955 名发作性偏头痛患者的 STRIVE 研究数据进行了事后分析。在每月偏头痛天数、每月偏头痛发作和平均偏头痛发作持续时间的双盲治疗阶段的第 4、5 和 6 个月内，从基线到平均值的相对变化进行了评估。

结果

与安慰剂相比，Erenumab 以类似的方式减少了每月偏头痛天数和每月偏头痛发作。Erenumab 对缩短偏头痛发作的持续时间只有很小的影响。

结论

这些事后分析表明，erenumab 每月偏头痛天数的减少主要是由于每月偏头痛发作频率的减少，而在较小程度上是由于偏头痛发作持续时间的缩短。

试验注册：本研究在 ClinicalTrials.gov 注册（NCT02456740）